Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02543710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarker Guided Treatment in Gynaecological Cancer

Study acronym: Momatec2
StatusRecruiting
PhasePhase 4
Started2015-10
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 28, 2017 (before its estimated December 2020 completion). Its status may not reflect the trial's current state.

Amendment history

2017-03-24
Study Identification, Study Status v4
Re-verified, no change to tracked fields
2017-03-08
Study Status, Contacts/Locations, IPDSharing v3
Study sites1→9
2016-08-23
Study Status v2
Re-verified, no change to tracked fields
2016-01-13
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2015-09→2015-10
Study sites0→1
2015-09-04
Original filing
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
Trial Details
NCT Number NCT02543710
Lead Sponsor Haukeland University Hospital
Conditions Endometrial Cancer
Enrollment 1,300 participants
Start Date 2015-10
Primary Completion 2020-12 (estimated)
Study Completion 2033-12 (estimated)
Updated on ClinicalTrials.gov 2017-03-28